NEW YORK, NY / ACCESSWIRE / January 11, 2018 / All three major indexes dropped Wednesday on news that China is considering halting the purchases of U.S. sovereign debt, with the S&P 500 and Nasdaq logging its first day in the red of 2018. Additionally, a report from Reuters stated that Canada is expecting President Donald Trump to pull the United States from the North American Free Trade Agreement. The Dow Jones Industrial Average declined 0.07 percent to close at 25,369.13, while the S&P 500 Index fell 0.11 percent to close at 2,748.23. The Nasdaq Composite Index dropped 0.14% to 7,153.57.
"If China stops buying Treasuries, the market could suffer," strategists at Jefferies said, according to CNBC. "Treasury financing needs are going to rise significantly in 2018 and beyond relative to recent history, so Treasury is going to be looking for as many sources of demand as they can find."
RDI Initiates Coverage on:
Sarepta Therapeutics, Inc.
Valeant Pharmaceuticals Intl Inc.
Sarepta Therapeutics stock jumped 5.33% Wednesday, to close the day at $59.14. The stock recorded a trading volume of 2,185,922 shares, which was above its three months average volume of 1,757,511 shares. In the last year, Sarepta Therapeutics shares have traded in a range of 26.26 - 59.95. The share price has gained 125.21% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $55.12 is greater than its 200-day moving average of $46.45. Shares of Sarepta Therapeutics have gained roughly 8.99 percent in the past month and are up 6.29 percent year-to-date.
Access RDI's Sarepta Therapeutics, Inc. Research Report at:
On Wednesday, shares of Valeant Pharmaceuticals recorded a trading volume of 11,788,904 shares, which was below the three months average volume of 18,337,563 shares. The stock ended the day 1.84% lower at 23.43. The share price has gained 181.95% from its 52-week low with a 52-week trading range of 8.31 - 24.43.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $19.87 is greater than its 200-day moving average of $15.88. Shares of Valeant Pharmaceuticals are trading at a Price to Earnings ratio of 5.98. Shares of Valeant Pharmaceuticals have gained roughly 18.93 percent in the past month and are up 12.75 percent year-to-date.
Access RDI's Windstream Holdings, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.